QualityStocksNewsBreaks Archives - Page 857 of 1422

MondayOct 05, 2020 11:46 am

QualityStocksNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Issues Corporate Update

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today provided a general corporate update. Among highlights provided in the update, LexaGene is in a strong position to support its development goals for the next year and beyond with its treasury currently standing at US$11.3 million (C$14.9 million). “Our MiQLab(TM) pathogen detection system has 230 unique components. Over the summer, the coronavirus pandemic caused some supply chain issues for several key components that delayed the manufacturing, optimization and testing of these systems. Just recently, these supply chain issues were resolved and…

MondayOct 05, 2020 10:54 am

QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Elects Leading International Expert as Board Chairman

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced the election of Dr. Roger McIntyre as chairman of its board of directors. A foremost international expert in depression and suicide, Dr. McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and holds appointments among scientific and clinical organizations across the United States and Asia. Dr. McIntyre was appointed to Champignon’s board in July 2020 and assumed the role of CEO in May 2020. He has set a strategic direction for the business, which…

MondayOct 05, 2020 10:21 am

QualityStocksNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Appoints Digital Media Exec as BIGtoken CEO

SRAX (NASDAQ: SRAX), a financial technology solutions provider, today announced that one of its board members, Malcolm CasSelle, will be appointed chief executive officer of BIGtoken, a wholly owned subsidiary of SRAX. In addition to his seven-year tenure on SRAX’s board of directors, CasSelle brings a close relationship with BIGtoken and more than 20 years of C-suite experience leading several startups in the digital media industry. “Malcolm brings years of experience in building technology companies,” SRAX CEO Christopher Miglino said in the news release. “He has the relationships and the know-how to bring the company to the next level and…

MondayOct 05, 2020 9:52 am

QualityStocksNewsBreaks – Youngevity International Inc. (NASDAQ: YGYI) Issues Update on Non-Compliance with Nasdaq Listing Requirements

Youngevity International (NASDAQ: YGYI), a leading multichannel lifestyle company operating in three distinct business segments, on Friday announced its receipt of a September 29, 2020, Staff Determination Letter (the "September Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC. According to the update, the letter indicated that Youngevity did not meet the terms of the exception previously granted to it by Nasdaq (the "Exception") pursuant to the notification letter received by the company on August 11, 2020. Under the Exception, in order to regain compliance with Nasdaq Listing Rule 5250(c)(1), the company was obligated to have filed…

FridayOct 02, 2020 2:27 pm

QualityStocksNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) CEO Discusses Strategic Business Models, Nascent Stage of B2C Platform

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and health-care platform, showcased its powerful capabilities during a recent virtual investor summit. Trxade Group’s CEO Suren Ajjarapu presented for the company to discuss the platform, which thrives on its business-to-business (“B2B”) model to provide radical transparency for drug pricing and availability while taking advantage of telehealth-friendly insurer policy shifts under its business-to-consumer (“B2C”) model. During his presentation, Ajjarapu highlighted comprehensive capabilities of the platform, including the vitality of its Bonum Health Hub portal-led B2C operations, serving approximately 15 million patients through the medium of over 11,700 independent pharmacies in its subscription…

FridayOct 02, 2020 1:56 pm

QualityStocksNewsBreaks – Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) Shares Road Map to Production, Promising Drill Program Results

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B),a Delaware corporation engaged in the acquisition, exploration and development of U.S. gold and silver properties, laid out its plan to become a profitable gold producer at the Aug. 6 OTCQB Virtual Investor Conference. Bullfrog was one of several companies hand selected to present to individual and institutional investors, advisors and analysts attending the event. A recent article discusses BFGC’s presentation and plans as the company’s CEO David Beling outlined the exciting potential of the Bullfrog Mining District of Nevada — the prolific location of BFGC properties — as well as promising…

FridayOct 02, 2020 1:43 pm

QualityStocksNewsBreaks – Mobius Interactive Ltd., UltraPlay to Enhance Customer Engagement Through Loyalty, Gamification Programs and Cutting-Edge Tech

Mobius Interactive, a new online gaming operator with a variety of diverse offerings, has partnered with leading eSports and iGaming platform — UltraPlay — to attract a global network of high-net-worth gamers. The two companies are collaborating to enhance customer engagement through the use of loyalty and gamification programs. A recent article discussing this reads, “Currently, Mobius is partnering with UltraPlay to offer more than 34 unique games and sports betting available 24/7. Mobius’ sports betting product has a wide range of functionalities, mystery jackpots, cutting-edge tech and live and pre-match odds. In addition, the company’s live casino games are…

FridayOct 02, 2020 1:28 pm

QualityStocksNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion

Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of experience and a recognition of psychedelics as a major breakthrough in treating mental health conditions. Amid the recent strong push for research and commercialization in the psychedelics sector, Drysdale seeks to pursue emerging opportunities and pave the road for the company’s rapid growth. “I am beyond excited to be joining the Cybin team,” Drysdale stated in a recent article of…

FridayOct 02, 2020 1:07 pm

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (https://ibn.fm/Y9fBZ). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 tumors in an effort to personalize cancer therapies and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Collins addressed this powerful work and his longtime passion during the interview titled, “Can We Cure Cancer with Artificial Intelligence?” “The last 20 years of…

FridayOct 02, 2020 12:46 pm

QualityStocksNewsBreaks – 180 Life Sciences Corp. Setting the Stage for Success in Bringing Novel Products to Market

180 Life Sciences, a clinical-stage biotechnology company, is focused on research to solve one of the world’s most significant drivers of disease – inflammation. The company currently has three programs for the development of novel drugs in the areas of fibrosis and anti-TNF, inflammatory pain and ulcerative colitis in ex-smokers. A recent article discusses the company’s strategy to expedite the path to market. The piece reads, “180 Life Sciences has mitigated the risks of its drug development through multiple programs at various stages of development. The company is actively decreasing costs and expediting the time to market by using grant…

Site Search

Company Search

Category: QualityStocksNewsBreaks